Valbenazine
VIDEO: Recent advancements in Huntington’s disease care
Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses valbenazine, a recent approval in Huntington's disease care.
Neurocrine announces four companies can market generic forms of Ingrezza
Neurocrine Biosciences has announced the resolution of litigation resulting from abbreviated new drug applications brought by companies that wished to market a generic version of Ingrezza before its patent expires.
VIDEO: Valbenazine improves chorea in Huntington’s disease
Healio spoke with Erin Furr Stimming, MD, about recent advancements and FDA approvals in Huntington’s disease.
FDA accepts new drug application for sprinkle form of Ingrezza capsules
The FDA has accepted a new drug application from Neurocrine Biosciences Inc. for its novel granule formulation of oral Ingrezza capsules, for those with tardive dyskinesia or chorea associated with Huntington’s disease.
Valbenazine improved chorea associated with Huntington’s as early as 2 weeks
A Southern California-based bioscience firm has announced additional positive data on FDA-approved Ingrezza capsules to treat adults with chorea associated with Huntington’s disease.
Valbenazine well-tolerated, improved chorea associated with Huntington’s disease
Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to research in The Lancet Neurology.
Adults with tardive dyskinesia more adherent to deutetrabenazine vs. valbenazine
CHICAGO — Adults with tardive dyskinesia prescribed deutetrabenazine had better adherence and were less likely to discontinue treatment compared with those on valbenazine, although the differences were not statistically significant.
Huntington Disease Health Index accurate for patient-reported changes in symptom burden
CHICAGO – The Huntington Disease Health Index was an accurate, clinically meaningful tool for participants in the KINECT-HD trial to report symptomatic disease burden changes when treated with valbenazine, according to a recent study.
Ingrezza may reduce chorea severity in Huntington’s disease
VIDEO: How pharmacologic treatments reduce symptoms of TD
Andres Deik, MD, assistant professor of clinical neurology and associate director of the Movement Disorders Fellowship Program at the University of Pennsylvania, discussed the importance of early recognition, screening patients for tardive dyskinesia symptoms at the first follow-up visit after prescribing the antipsychotic and using a multidisciplinary approach to optimize care coordination for patients with, or at risk for, TD.